NASDAQ:BCTX

BriaCell Therapeutics (BCTX) Stock Forecast, Price & News

$5.56

+0.05 (+0.91%)

(As of 09/26/2023 ET)

Compare

Today's Range: $5.42
▼
$5.69
50-Day Range: $5.42
▼
$7.53
52-Week Range: $4.23
▼
$8.10

Volume: 28,202 shs
Average Volume: 87,745 shs
Market Capitalization: $88.85 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $25.00

BriaCell Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 349.6% Upside
$25.00 Price Target
Short Interest: Bearish
8.55% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.56) to ($1.40) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

882nd out of 963 stocks

Pharmaceutical Preparations Industry

417th out of 452 stocks

3.5

Analyst's Opinion

Consensus Rating
BriaCell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $25.00, BriaCell Therapeutics has a forecasted upside of 349.6% from its current price of $5.56.
Amount of Analyst Coverage
BriaCell Therapeutics has received no research coverage in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
8.55% of the float of BriaCell Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
BriaCell Therapeutics has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.
Change versus previous month
Short interest in BriaCell Therapeutics has recently increased by 3.67%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
BriaCell Therapeutics does not currently pay a dividend.
Dividend Growth
BriaCell Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BCTX.

3.8

News and Social Media Coverage

News Sentiment
BriaCell Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for BriaCell Therapeutics this week, compared to 0 articles on an average week.
MarketBeat Follows
1 people have added BriaCell Therapeutics to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BriaCell Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
22.20% of the stock of BriaCell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 17.33% of the stock of BriaCell Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for BriaCell Therapeutics are expected to grow in the coming year, from ($1.56) to ($1.40) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BriaCell Therapeutics is -2.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BriaCell Therapeutics is -2.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BriaCell Therapeutics has a P/B Ratio of 8.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About BriaCell Therapeutics (NASDAQ:BCTX) Stock

BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

BCTX Price History

30 days | 90 days | 365 days | Advanced Chart

BCTX Stock News Headlines

August 31, 2023 | finance.yahoo.com

BriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing Shareholders

August 31, 2023 | finance.yahoo.com

BriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT™ in High-Risk Early-Stage Triple Negative Breast Cancer

September 27, 2023 | Wall Street Fundamentals (Ad)

The "Plug and Play" Model Putting Online Giants to Shame

While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."

August 28, 2023 | bizjournals.com

BriaCell receives court approval to launch spinoff aimed at accelerating cancer drug development

July 10, 2023 | finance.yahoo.com

BCTX: Pivotal Study Protocol Cleared

June 28, 2023 | benzinga.com

HC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $25 Price Target

June 27, 2023 | baystreet.ca

Five Top Companies Fighting for the Treatment of Metastatic Breast Cancer

June 27, 2023 | finance.yahoo.com

FDA Approves BriaCell’s Pivotal Registrational Study Design in Advanced Metastatic Breast Cancer

September 27, 2023 | Wall Street Fundamentals (Ad)

The "Plug and Play" Model Putting Online Giants to Shame

May 25, 2023 | baystreet.ca

There are Positive Developments in the Treatment of Metastatic Breast Cancer

May 15, 2023 | baystreet.ca

Five Impressive Metastatic Cancer Treatment Stocks to Own Today

May 15, 2023 | finance.yahoo.com

BriaCell Announces $4 Million Strategic Investment and Clinical Alliance with Prevail Partners, LLC and Prevail InfoWorks, Inc.

April 27, 2023 | finance.yahoo.com

BCTX: Posters Galore at AACR

April 10, 2023 | finance.yahoo.com

BriaCell Therapeutics (TSE:BCT) Is In A Good Position To Deliver On Growth Plans

March 30, 2023 | seekingalpha.com

BriaCell plans spin-out of some pre-clinical assets into new entity

March 24, 2023 | finanznachrichten.de

USA News Group: Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer

March 14, 2023 | finance.yahoo.com

A BriaCell Therapeutics Corp. (TSE:BCT) insider increased their holdings by 20% last year

March 9, 2023 | finance.yahoo.com

BCTX: 82% Survival Benefit

February 28, 2023 | seekingalpha.com

BCTX BriaCell Therapeutics Corp.

January 20, 2023 | finance.yahoo.com

Lab Notes: Amicus founder gets national honor; Capstan and Code Bio land on list of companies to watch

December 19, 2022 | finance.yahoo.com

BCTX: Down in San Antone

December 1, 2022 | benzinga.com

BriaCell's Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients

November 10, 2022 | finance.yahoo.com

BriaCell Reports Positive Breast Cancer Efficacy Data with Bria-IMT™ Immunotherapy Treatment at SITC Annual Meeting

October 31, 2022 | finance.yahoo.com

BCTX: Fiscal Year 2022 Results

October 14, 2022 | finance.yahoo.com

Here's Why We're Not Too Worried About BriaCell Therapeutics' (TSE:BCT) Cash Burn Situation

October 12, 2022 | finance.yahoo.com

BriaCell Announces New Clinical Trial Site to Bring Novel Cancer Treatments to Advanced Breast Cancer Patients

September 9, 2022 | benzinga.com

BriaCell Announces Presentation at the 2022...

See More Headlines

Receive BCTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCTX Company Calendar

Today: 9/27/2023
Next Earnings (Estimated): 10/26/2023
Fiscal Year End: 7/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BCTX
CUSIP: N/A
CIK: 1610820
Web: www.briacell.com
Phone: (604) 921-1810
Fax: 604-921-1898
Employees: 5
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $25.00
High Stock Price Forecast: $25.00
Low Stock Price Forecast: $25.00
Forecasted Upside/Downside: +349.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.17)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-26,840,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -997.24%
Return on Assets: -92.84%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 21.33
Quick Ratio: 21.33

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.67 per share
Price / Book: 8.30

Miscellaneous

Outstanding Shares: 15,980,000
Free Float: 12,434,000
Market Cap: $88.85 million
Optionable: Not Optionable
Beta: 1.24

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. William V. Williams M.D. (Age 67)
CEO, Pres & Director
Comp: $710.99k

Mr. Gadi Levin B.Com. (Age 50)
C.A., CPA, M.B.A., MBA, CFO & Corp. Sec.
Comp: $247.09k

Dr. Miguel A. Lopez-Lago (Age 54)
Chief Scientific Officer
Comp: $246.62k

Dr. Giuseppe Del Priore M.D. (Age 61)
M.P.H., MPH, Chief Medical Officer
Comp: $438.86k

Dr. Charles Louis Wiseman FACP (Age 77)
M.D., Founder, Principal Research Advisor & Member of Scientific Advisory Board

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BCTX Stock - Frequently Asked Questions

Should I buy or sell BriaCell Therapeutics stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BriaCell Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BCTX shares.
View BCTX analyst ratings or view top-rated stocks.
What is BriaCell Therapeutics' stock price forecast for 2023?: 1 analysts have issued 1 year price objectives for BriaCell Therapeutics' stock. Their BCTX share price forecasts range from $25.00 to $25.00. On average, they predict the company's share price to reach $25.00 in the next year. This suggests a possible upside of 349.6% from the stock's current price.
View analysts price targets for BCTX or view top-rated stocks among Wall Street analysts.
How have BCTX shares performed in 2023?: BriaCell Therapeutics' stock was trading at $4.37 on January 1st, 2023. Since then, BCTX stock has increased by 27.2% and is now trading at $5.56.
View the best growth stocks for 2023 here.
When is BriaCell Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our BCTX earnings forecast.
When did BriaCell Therapeutics IPO?: (BCTX) raised $15 million in an initial public offering on Wednesday, February 24th 2021. The company issued 3,300,000 shares at $4.25-$5.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO.

What is BriaCell Therapeutics' stock symbol?: BriaCell Therapeutics trades on the NASDAQ under the ticker symbol "BCTX."
Who are BriaCell Therapeutics' major shareholders?: BriaCell Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wasatch Advisors LP (3.83%), Natixis (0.56%), K.J. Harrison & Partners Inc (0.22%), Bank of Montreal Can (0.22%), Concord Wealth Partners (0.10%) and Simplex Trading LLC (0.00%).
View institutional ownership trends.
How do I buy shares of BriaCell Therapeutics?: Shares of BCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is BriaCell Therapeutics' stock price today?: One share of BCTX stock can currently be purchased for approximately $5.56.
How much money does BriaCell Therapeutics make?: BriaCell Therapeutics (NASDAQ:BCTX) has a market capitalization of $88.85 million. The company earns $-26,840,000.00 in net income (profit) each year or ($2.17) on an earnings per share basis.
How can I contact BriaCell Therapeutics?: BriaCell Therapeutics' mailing address is 3RD FLOOR BELLEVUE CENTRE 235-15TH STR, WEST VANCOUVER A1, V7T 2X1. The official website for the company is www.briacell.com. The company can be reached via phone at (604) 921-1810, via email at investors@briacell.com, or via fax at 604-921-1898.

This page (NASDAQ:BCTX) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial